FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

washington, D.C. 2054	19

OIVID APPROVAL										
OMB Number:	3235-0287									
Estimated average bu	ırden									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(n). See Instruction 10

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  MCHUGH THOMAS S  The standard Holds of Reporting Person*						2. Issuer Name and Ticker or Trading Symbol AVADEL PHARMACEUTICALS PLC AVDL ]								5. Relationship of Reportin (Check all applicable) Director  Officer (give title below)				on(s) to Is  10% Ov  Other (solution)	wner
(Last) (First) (Middle)  C/O AVADEL PHARMACEUTICALS PLC  10 EARLSFORT TERRACE						3. Date of Earliest Transaction (Month/Day/Year) 12/11/2024								Chief Financial Officer					
(Street) DUBLIN (City)	I 2 L2		002 T3	380	4. If /	4. If Amendment, Date of Original Filed (Month/Day/Year)								ine)	ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Table	I - No	on-Deriva	tive \$	Secui	rities	Acc	quire	d, Dis	sposed of	, or E	Benefic	ially	Own	ed			
1. Title of Security (Instr. 3)  2. Transactio Date (Month/Day/N						Execution Date,			3. Transaction Code (Instr. 8)  4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4					and 5) Secu Bene		cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
										v	Amount	(A) or (D)	Price		Transa	action(s) . 3 and 4)			(IIISU. 4)
Ordinary Shares 12/11/20					024				P		5,000	A	\$10.4	865	865 85,500		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution D Gecurity or Exercise (Month/Day/Year) if any			ıtion Date,	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date			7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		Der Sec (Ins	rice of ivative urity tr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4		Beneficial Ownership (Instr. 4)
					Code V		(A)	(D)	Date Exercisable		Expiration Date	Title	Number of Shares						

**Explanation of Responses:** 

/s/ Jerad G. Seurer, Attorney-

12/12/2024

Date

in-Fact

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.